

1 **Clinical evaluation of a fully automated, lab developed multiplex RT-PCR**  
2 **assay integrating dual-target SARS-CoV-2 and Influenza-A/B detection on a**  
3 **high-throughput platform**

4 Dominik Nörz<sup>1</sup>, Armin Hoffmann<sup>1</sup>, Martin Aepfelbacher<sup>1</sup>, Susanne Pfefferle<sup>1\*</sup> and Marc  
5 Lütgehetmann<sup>1\*</sup>

6 <sup>1</sup> University Medical Center Hamburg-Eppendorf (UKE), Institute of Medical Microbiology, Virology  
7 and Hygiene, Hamburg, Germany

8  
9 \* Equal contribution

10 **Highlights:**

- 11 • **Simultaneous detection of highly pathogenic respiratory viruses Influenza-A/B and**  
12 **SARS-CoV-2**
- 13 • **Including a dual-target assay for SARS-CoV-2 detection**
- 14 • **Full automation on the cobas6800 high-throughput platform**

15  
16  
17  
18  
19  
20  
21  
22  
23 **Address correspondence to:**

24  
25 Marc Lütgehetmann  
26 Institute of Medical Microbiology, Virology and Hygiene  
27 Martinistraße 52  
28 D-20246 Hamburg  
29 mluetgeh@uke.de

30

## 31     **1 Abstract**

32     **Background:** Laboratories worldwide face high demands for molecular testing during the  
33     SARS-CoV-2 pandemic that might be further aggravated with the upcoming influenza season  
34     in the northern hemisphere. Considering that symptoms of influenza are largely  
35     undistinguishable from COVID-19, both SARS-CoV-2 and the Influenza viruses require  
36     concurrent testing by RT-PCR in patients presenting with symptoms of respiratory tract  
37     infection. In this study, we adapted and evaluated a laboratory developed multiplex RT-PCR  
38     assay for simultaneous detection of SARS-CoV-2 (dual-target), Influenza-A and Influenza-B  
39     (SC2/InflA/InflB-UCT) on a fully automated high-throughput system (cobas6800). **Methods:**  
40     Analytical performance was assessed by serial dilution of quantified reference material and  
41     cell culture stocks in transport medium, including pre-treatment for chemical inactivation.  
42     For clinical evaluation, residual portions of 164 predetermined patient samples containing  
43     SARS-CoV-2 (n=52), Influenza-A (n=43) or Influenza-B (n=19), as well as a set of negative  
44     samples was subjected to the novel multiplex assay. **Results:** The assay demonstrated  
45     analytical performance comparable to currently available commercial tests, with limits of  
46     detection of 94.9 cp/ml for SARS-CoV-2, 14.6 cp/ml for Influenza-A and 422.3 cp/ml for  
47     Influenza-B. Clinical evaluation showed excellent agreement with the comparator assays  
48     (sensitivity 98.1%, 97.7% and 100% for Sars-CoV-2, Influenza-A and -B respectively).  
49     **Conclusion:** The SC2/InflA/InflB-UCT allows for efficient high-throughput testing for all three  
50     pathogens and thus provides streamlined diagnostics while conserving resources during the  
51     Influenza-season.

## 52     **2 Introduction:**

53     The upcoming Influenza-season of 2020/21 will further aggravate the strain on diagnostic  
54     laboratories, already facing unprecedented demand for molecular diagnostics due to the  
55     ongoing SARS-CoV-2 pandemic. Just like COVID-19, Influenza is a major concern for infection  
56     control within healthcare facilities and symptoms are largely indistinguishable, particularly in  
57     the early phase of disease (1, 2). Consequently, SARS-CoV-2 and the Influenza viruses need  
58     to be concurrently tested for by RT-PCR before contact precaution measures can be lifted for  
59     symptomatic patients. In light of the continuing worldwide shortage of supplies for nucleic  
60     acid extraction and PCR diagnostics, it appears desirable to be able to screen for all three  
61     viruses (SARS-CoV-2, Influenza-A and Influenza-B) within the same reaction.

62     The cobas6800 system is a fully automated sample-to-result high-throughput platform,  
63     requiring minimal hands-on-time and able to perform up to 384-tests in an 8-hour shift. The  
64     instrument was previously evaluated for the detection of Influenza viruses in respiratory  
65     swabs (3) and is currently seeing increasing use for automated SARS-CoV-2 diagnostics (4, 5).

66     The aim of this study was to establish and evaluate a multiplex assay for the detection of  
67     SARS-CoV-2, Influenza-A and Influenza-B on the open mode of the cobas6800 system (cobas  
68     omni utility channel).

## 69     **3 Materials and Methods**

### 70     ***3.1 SC2/InfIA/InfIB-UCT setup and preparation***

71     A set of published RT-PCR assays for SARS-CoV-2, Influenza-A- and Influenza-B virus was  
72     selected and adapted for use on the cobas6800 system, see *table 1* (6-10). Primers were

73 modified with 2'-O-methylated RNA-bases at their penultimate positions to reduce formation  
 74 of primer dimers. Double-quenched probes were used to lower background-fluorescence. All  
 75 primers and probes were tested for contaminations prior to use, in particular concerning  
 76 material reactive for SARS-CoV-2 in custom made commercial primers.

Target	Primer/Probe	Sequence (5' - 3')	Conc. [nM]	Indusivity	Ref.
<b>SARS-CoV-2 E-Gene</b>	Fwd:	ACAGGTA CGTTAATA GTTAATAGC(OMe-G)T	400	<b>Sarbecovirus</b> (SARS-CoV, SARS-CoV-2)	[6]
	Rev:	ATATTGCA GCA GTACG CACA(OMe-C)A	400		
	Probe:	Fam- A CA CTA GCC(ZEN-NFQ)ATCCTTACTGCGCTTCG -lowaBlack	50		
<b>SARS-CoV-2 RdRp/Hel</b>	Fwd:	CGCATACAGTCTTACAGG(OMe-C)T	300	<b>SARS-CoV-2</b>	[7]
	Rev:	TGTGATGTTGATATGATATGG(OMe-U)C	300		
	Probe:	Fam- TTAAGATGT(ZEN-NFQ)GGTGCTTGATA CGTAGAC -lowaBlack	50		
<b>Influenza A M</b>	Fwd:	CTTCTAACCGAGGTCGAAACG(OMe-U)A	300	<b>Pan-Influenza-A</b> (incl. avian H5 and H7)	[8,9]
	Rev:	GGTGACAGGATTGGTCTTGCTT(OMe-U)A	300		
	Probe:	YakYel- TCAGGCCCC(ZEN-NFQ)CTCAAAGCCGAG -lowaBlack	50		
<b>Influenza B NS2</b>	Fwd:	TCCTCAA Y TCACTCTTCGAG(OMe-C)G	300	<b>Pan-Influenza-B</b>	[10]
	Rev:	CGGTGCTCTTGACCAATT(OMe-G)G	300		
	Probe:	Atto620- CCAATTCGA(BMN-Q620)GCAGCTGAAACTGCGGTG -BMN-Q620	50		

77

78 *Table 1: Assays used for the SC2/InflA/InflB-UCT. Primers and probes were custom made and*  
 79 *procured from Integrated DNA Technologies (Illinois, USA), Biomers.net GmbH (Ulm, Germany) and*  
 80 *Ella Biotech GmbH (Martinsried, Germany). OMe, 2'-O-methyl RNA; NFQ, Non-fluorescent quencher;*  
 81 *YakYel, Yakima Yellow*

82 Primers and probes were diluted in MMX-R2-reagent to final concentrations as indicated  
 83 above (*table 1*) to form the MMR2-Mastermix (MMRX-R2-reagent already contains the  
 84 internal control assay by default). 6 ml of MMR2-Mastermix were loaded into cobas omni  
 85 utility channel cassettes according to instructions by the manufacturer. The run profile for  
 86 the SC2/InflA/InflB-UCT multiplex assay was configured using the cobas omni Utility Channel  
 87 Software as indicated in *table 2*.

88

Software settings					
Sample type	Alcohol Based Sample (400 µL)				
Channels	1: (Not assigned)	2: SC2	3: InflA	4: InflB	5: IC
RFI		1.25	1.25	1.25	1.15
PCR cycling conditions					
	UNG incubation	Pre-PCR step	1 <sup>st</sup> measurement	2 <sup>nd</sup> measurement	Cooling
No. of cycles	Predefined	1	5	45	Predefined
No. of steps		3	2	2	
Temperature		55°C; 60°C; 65°C	95°C; 55°C	91°C; 58°C	
Hold time		120 s; 360 s; 240 s	5 s; 30 s	5 s; 25 s	
Data acquisition		None	End of each cycle	End of each cycle	

89

90 *Table 2: Run-profile for the SC2/InflA/InflB, set up using the cobas omni utility channel tool.*

91

### 92 **3.2 Limit of detection (LoD), linearity and cross-reactivity**

93 Analytical limit of detection (LoD) was determined for all three targets simultaneously by  
 94 serial dilution of reference material in Amies medium including cobas PCR Media (1:1) as  
 95 matrix. For SARS-CoV-2, a stock of cell culture supernatant containing SARS-CoV-2 (11) was  
 96 quantified using the SARS-CoV-2 IVD Test for the cobas6800 (12) with the Qnostics “SARS-  
 97 CoV-2 Q Control 01” as reference for quantification. For Influenza-A and Influenza-B,  
 98 reference material was acquired from Qnostics (“INFA Medium Q Control 01” and “INFB  
 99 Medium Q Control 01”) and used directly for LoD experiments. A total of 8 different

100 concentrations was tested with 8 repeats each. (SC2 [cp/ml]-InflA [cp/ml]-InflB [cp/ml],  
101 1000-1000-2000, 333-333-666, 100-100-200, 50-50-100, 25-25-50, 10-10-20, 3-3-6, 1-1-2)  
102 Linearity was determined for all targets simultaneously by 10-fold serial dilution, 5 repeats  
103 each step, using cell culture supernatant and Vaxigrip Tetravalent Influenza vaccine (Sanofi  
104 Pasteur, France) to spike Amies medium including cobas PCR Media (1:1) (*Figure 1*).  
105 Inclusivity and cross-reactivity were verified using external quality control panels by  
106 INSTAND e.V. (Düsseldorf, Germany) and clinical samples containing a variety of respiratory  
107 pathogens, including endemic human coronaviruses (see *table 4*).

### 108 **3.3 Clinical samples**

109 For clinical evaluation, a total of 164 archived predetermined respiratory swab samples were  
110 subjected to the SC2/InflA/InflB-UCT. Clinical samples were oropharyngeal or  
111 nasopharyngeal swabs, performed using eSwab sample collection kits (Copan, Italy),  
112 containing 1 ml Amies-Medium. 1 – 2 ml of cobas PCR Media ( $\leq 40\%$  guanidine  
113 hydrochloride in Tris-HCL buffer) were added to samples prior to analysis in routine  
114 diagnostics. Samples were stored up to three months at  $-20^{\circ}\text{C}$  for SARS-CoV-2 and up to  
115 three years for Influenza-A/B.  
116 SARS-CoV-2 samples were included if positive for Target-1 and Target-2 of the SARS-CoV-2  
117 IVD assay. The Cepheid Xpert Xpress Flu/RSV assay was used to resolve discrepant results for  
118 Influenza-A/B virus. Samples predetermined positive (by inhouse methods) for Influenza-A  
119 or Influenza-B that tested negative in the SC2/InflA/InflB-UCT were included in the study  
120 only if tested positive for both Influenza-A targets or positive for Influenza-B in the Xpert  
121 Xpress Flu/RSV-assay.

122 This work was conducted in accordance with §12 of the Hamburg hospital law (§12  
123 HmbKHG). The use of anonymized samples was approved by the ethics committee, Freie und  
124 Hansestadt Hamburg, PV5626.

## 125 4 Results

### 126 4.1 Analytical performance

127 Analytical LoD was determined by Probit-Analysis as 94.9 cp/ml (95% CI: 40.5 – 222.0 cp/ml)  
128 for SARS-CoV-2, 14.57 cp/ml (95% CI: 6.7 – 31.6 cp/ml) for Influenza-A and 422.3 cp/ml (95%  
129 CI: 213.8 – 834.4 cp/ml) for Influenza-B (*table 3*).

130

SC2/InfIA/InfIB-UCT Limit of Detection (LoD)


SARS-CoV-2		Influenza-A		Influenza-B	
Conc. [cp/ml]	Pos./Rep.*	Conc. [cp/ml]	Pos./Rep.*	Conc. [cp/ml]	Pos./Rep.*
1000	8/8	1000	8/8	2000	8/8
333	8/8	333	8/8	666	8/8
100	8/8	100	8/8	200	7/8
50	8/8	50	8/8	100	8/8
25	8/8	25	8/8	50	6/8
10	6/8	10	8/8	20	5/8
3	0/8	3	6/8	6	2/8
1	3/8	1	4/8	2	0/8
0	0/8	0	0/8	0	0/8

131

132 *Table 3: Quantified cell culture stocks and quantified reference material (by Qnostics) was*  
133 *spiked into 1:1 cobas PCR Media in eSwab medium. LOD was determined for all targets*  
134 *simultaneously, meaning that every sample contained the indicated concentrations of each*  
135 *pathogen for each dilution step. \* Number of positives / Number of total repeats*

136

137 The assay showed good linearity for all targets up to a CT value (cycle threshold) of 33  
138 (Figure 1).



139

140 *Figure 1: Linearity was determined for all targets simultaneously by serial dilution of SARS-*  
141 *CoV-2 cell culture stocks and Vaxigrip Tetraivalent Influenza vaccine in 1:1 cobas PCR Media*  
142 *in eSwab medium. X-axis: dilution factor.*

143

144 In cross-reactivity experiments, no false positives occurred. Avian Influenza-A strains H7N9  
145 and H5N8 were correctly detected by the multiplex assay, demonstrating broad coverage  
146 (table 4). Nonetheless, it is recommended to verify inclusivity of primer/probe sequences as  
147 new Influenza-A strains continuously emerge.



148

<u>External Quality Control Panel</u>				
Species	Number tested	Target: SC2	Target: InflA	Target: InflB
Influenza A H1N1 pdm09 ( <i>A/Michigan/45/2015</i> )	1	Negative	<b>Positive</b>	Negative
Influenza A H7N9 ( <i>A/Anhui/1/2013</i> )	1	Negative	<b>Positive</b>	Negative
Influenza A H5N8 ( <i>A/DE-SH/Reiherente/AR8444/2016</i> )	1	Negative	<b>Positive</b>	Negative
Influenza B Yamagata ( <i>B/Phuket/3073/2013</i> )	1	Negative	Negative	<b>Positive</b>
Influenza B Victoria ( <i>B/Colorado/06/2017</i> )	1	Negative	Negative	<b>Positive</b>
Human Coronavirus 229E	1	Negative	Negative	Negative
Human Coronavirus OC43	1	Negative	Negative	Negative
MERS Coronavirus	1	Negative	Negative	Negative
Parainfluenzavirus 2	1	Negative	Negative	Negative
<u>Clinical samples</u>				
Species		Target: SC2	Target: InflA	Target: InflB
Human Coronavirus HKU1	2	Negative	Negative	Negative
Human Coronavirus NL63	1	Negative	Negative	Negative
Human Coronavirus OC43	1	Negative	Negative	Negative
Boca-virus	1	Negative	Negative	Negative
Parainfluenzavirus 3	1	Negative	Negative	Negative
Human Metapneumovirus	2	Negative	Negative	Negative
Rhino-/Enterovirus	3	Negative	Negative	Negative
Respiratory Syncytial Virus	2	Negative	Negative	Negative
Mycoplasma pneumoniae	1	Negative	Negative	Negative
Chlamydia pneumoniae	1	Negative	Negative	Negative
Pneumocystis jirovecii	1	Negative	Negative	Negative

149

150 *Table 4: Inclusivity and cross-reactivity. A panel of clinical samples containing respiratory*  
 151 *pathogens, as well as relevant external quality control panel samples (INSTAND e.V.) were*  
 152 *tested with the SC2/InflA/InflB-UCT. No false positives occurred.*

153 **4.2 Evaluation of clinical performance**

154 Sensitivity in clinical samples containing respective targets was 98.1% for SARS-CoV-2 (52  
 155 samples, median CT: 31.99, IQR: 27.21 – 33.96), 97.67% for Influenza-A (43 samples of which  
 156 15 were subtyped as H1N1, median CT: 27.80, IQR: 24.85 – 31.1) and 100% for Influenza-B  
 157 (19 samples, median CT: 29, IQR: 28 - 30), see *table 5*.

158

		Predetermined clinical specimen			
		SARS-CoV2	Influenza-A	Influenza-B	Negative*
SC2/InfIA/InfIB-UCT	SC2 positive	51/52	0/43	0/19	0/109
	InfIA positive	0/52	42/43	0/19	0/118
	InfIB positive	0/52	0/43	19/19	0/142
	Negative	1/52	1/43	0/19	47/47
	Total:	52	43	19	369†

159

160

161 *Table 5: 164 clinical samples were tested in total, predefined positive for SARS-CoV-2 via*  
 162 *SARS-CoV-2 IVD test for the cobas6800 system; predefined positive for Influenza-A or -B*  
 163 *by established inhouse methods or Xpert Xpress Influenza/RSV. Invalid rate was 6.4%*  
 164 *(invalids not included in the table). Samples were stored at -20°C between 1 and 36 months.*


165 *\* Total of samples negative for respective target. † Sum of all predefined negative*  
 166 *samples for each individual pathogen. This includes 47 samples negative for all three*  
 167 *pathogens.*

168

169 CT values showed good correlation with the SARS-CoV-2 IVD, see *figure 2*. For SARS-CoV-2 a  
 170 single false negative occurred for a sample containing very low amounts of viral RNA,

171 approximately 184 cp/ml. Another false negative occurred for Influenza A in a sample with  
172 low viral load (Xpert Flu/RSV, A1 CT: 33, A2 CT: 35)

173



174

175

176 *Figure 2: The SC2/InfA/InfB-UCT SC2-CT was compared to the SARS-CoV-2 IVD Target-2 CT*

177 *(used for quantification and best in regards to linear range) to illustrate correlation with a*

178 *well-established assay. Red diamond indicates false negative for the multiplex assay. ND =*

179 *Not detected.*

180

181 A total of 50 predetermined samples negative for SARS-CoV-2 (by SARS-CoV-2 IVD) and  
182 Influenza-A/B (by LDT assay) were subjected to the SC2/InflA/InflB-UCT. No false positives  
183 occurred; inhibition rate in eSwab samples was 6.4%.

184 As a proof of concept, a dilution series of a SARS-CoV-2 positive patient sample was  
185 prepared and subjected to testing in the presence and absence of high levels of Influenza-A-  
186 and Influenza-B-RNA (*supplement figure 1*). No relevant impact on SARS-CoV-2 detection  
187 was observed.

188

## 189 **5 Discussion**

190 In this study we present a functional SARS-CoV-2/Influenza-A/Influenza-B multiplex assay for  
191 the cobas6800 high-throughput platform, featuring analytical and clinical performance  
192 comparable to currently used methods for the detection of these pathogens in clinical  
193 specimens. The ability to screen for all three viruses in a single reaction allows for  
194 streamlined workflows and conservation of resources during the coming Influenza-season.

195 By this time, multiple commercial providers have announced, or are in the process of rolling  
196 out multiplex-assays for detection of SARS-CoV-2, Influenza-A/B and RSV. However, these  
197 are for the most part designed for a point-of-care rapid testing approach and not high-  
198 throughput testing. Moreover, the CDC has itself recently published primer-sets for a SARS-  
199 CoV-2/Influenza-A/Influenza-B multiplex assay, which relies on manual PCR workflows (10).  
200 However, the ability to employ inhouse assays on fully automated PCR platforms provides  
201 vastly improved scalability of testing capacity and less limitations due to availability of  
202 trained personnel.

203 Most currently available commercial SARS-CoV-2 tests with FDA emergency authorization  
204 are designed as multi-target assays to account for emerging mutations. While the original  
205 Sarbeco-E primerset by Corman et al. (6) resides in a particularly stable region of the SARS-  
206 CoV-2 genome, single mutations have been reported within the ever-growing catalogue of  
207 available whole genome sequences (13). The RdRp/Hel assay by Chan et al. (7) was modified  
208 and adapted as a second target to provide additional security for inclusivity in SARS-CoV-2  
209 detection. Both assays were allocated to the same channel as positivity of any single one  
210 would constitute a positive result. There was no indication that presence of Influenza-A  
211 and/or Influenza-B RNA within the reaction substantially impairs sensitivity for SARS-CoV-2.  
212 If necessary, each SARS-CoV-2 assay can be analysed separately by moving RdRp/Hel  
213 detection to channel 1, using the following probe (or comparable): 5' Atto425-  
214 TTAAGATGT(BMN-Q535)GGTGCTTGCATACGTAGAC -BMN-Q535 3' (*see supplement figure 2*).  
215 It has to be acknowledged that the SARS-CoV-2 assays used for this multiplex-setup are  
216 technically not specific for SARS-CoV-2 but for the Sarbeco-subgenus of betacoronaviruses,  
217 including SARS-CoV (from 2003) and SARS-like bat viruses.

218 In conclusion, we provide analytical and clinical evaluation of a SARS-CoV-2/Influenza-  
219 A/Influenza-B multiplex assay for the cobas6800 high-throughput platform. Performance for  
220 each target was comparable to existing solutions currently in use in diagnostic practice. Our  
221 novel assay may prove useful for streamlining diagnostics during the upcoming Influenza-  
222 season.

223

## 224 **6 Author contribution**

225 Conceptualization: DN, MA, SP, and ML. Methodology and Investigation: DN. Original draft  
226 preparation: DN and SP. Review and editing: DN, AH, MA, SP and ML Supervision: SP and ML.  
227 All authors agreed to the publication of the final manuscript.

228

## 229 **7 Competing interest**

230 ML received speaker honoraria and related travel expenses from Roche Diagnostics.

231 All other authors declare no conflict of interest.

232

## 233 **References:**

- 234 1. Wu Z, McGoogan JM. 2020. Characteristics of and Important Lessons From the Coronavirus  
235 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the  
236 Chinese Center for Disease Control and Prevention. JAMA doi:10.1001/jama.2020.2648.
- 237 2. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y, Fullerton  
238 KE. 2020. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30,  
239 2020. MMWR Morbidity and mortality weekly report 69:759-765.
- 240 3. Eigner U, Reucher S, Hefner N, Staffa-Peichl S, Kolb M, Betz U, Holfelder M, Spier G, Pfefferle  
241 S, Lutgehetmann M. 2019. Clinical evaluation of multiplex RT-PCR assays for the detection of  
242 influenza A/B and respiratory syncytial virus using a high throughput system. J Virol Methods  
243 269:49-54.
- 244 4. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. 2020. Evaluation of a quantitative RT-PCR  
245 assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput  
246 system. Eurosurveillance 25:2000152.
- 247 5. Poljak M, Korva M, Knap Gašper N, Fujs Komloš K, Sagadin M, Uršič T, Avšič Županc T,  
248 Petrovec M. 2020. Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform  
249 switch during 48 hours in the midst of the COVID-19 pandemic. Journal of Clinical  
250 Microbiology doi:10.1128/jcm.00599-20:JCM.00599-20.
- 251 6. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S,  
252 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,  
253 Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,

- 254 Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-  
255 time RT-PCR. *Euro Surveill* 25.
- 256 7. Chan JF-W, Yip CC-Y, To KK-W, Tang TH-C, Wong SC-Y, Leung K-H, Fung AY-F, Ng AC-K, Zou Z,  
257 Tsoi H-W, Choi GK-Y, Tam AR, Cheng VC-C, Chan K-H, Tsang OT-Y, Yuen K-Y. 2020. Improved  
258 Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-  
259 RdRp/HeI Real-Time Reverse Transcription-PCR Assay Validated *In Vitro* and with  
260 Clinical Specimens. *Journal of Clinical Microbiology* 58:e00310-20.
- 261 8. WHO. 2017. WHO information for the molecular detection of influenza viruses. WHO  
262 Website.
- 263 9. Terrier O, Josset L, Textoris J, Marcel V, Cartet G, Ferraris O, N'Guyen C, Lina B, Diaz J-J,  
264 Bourdon J-C, Rosa-Calatrava M. 2011. Cellular transcriptional profiling in human lung  
265 epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-  
266 regulation of the host p53 pathway. *Virology journal* 8:285-285.
- 267 10. CDC. 2020. Research Use Only CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay Real-Time  
268 RT-PCR Primers and Probes. CDC Website.
- 269 11. Pfefferle S, Huang J, Nörz D, Indenbirken D, Lütgehetmann M, Oestereich L, Günther T,  
270 Grundhoff A, Aepfelbacher M, Fischer N. 2020. Complete Genome Sequence of a SARS-CoV-2  
271 Strain Isolated in Northern Germany. *Microbiology Resource Announcements* 9:e00520-20.
- 272 12. Nörz D, Frontzek A, Eigner U, Oestereich L, Fischer N, Aepfelbacher M, Pfefferle S,  
273 Lütgehetmann M. 2020. Pushing beyond specifications: Evaluation of linearity and clinical  
274 performance of a fully automated SARS-CoV-2 RT-PCR assay for reliable quantification in  
275 blood and other materials outside recommendations. medRxiv  
276 doi:10.1101/2020.05.28.20115469:2020.05.28.20115469.
- 277 13. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, Petrone ME, Casanovas-  
278 Massana A, Catherine Muenker M, Moore AJ, Klein J, Lu P, Lu-Culligan A, Jiang X, Kim DJ,  
279 Kudo E, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Tokuyama  
280 M, Venkataraman A, Weizman O-E, Wong P, Yang Y, Cheemarla NR, White EB, Lapidus S,  
281 Earnest R, Geng B, Vijayakumar P, Odio C, Fournier J, Bermejo S, Farhadian S, Dela Cruz CS,  
282 Iwasaki A, Ko AI, Landry ML, Foxman EF, Grubaugh ND. 2020. Analytical sensitivity and  
283 efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. *Nature Microbiology*  
284 doi:10.1038/s41564-020-0761-6.
- 285
- 286
- 287

## 288 **8 Figure legend**

### 289 **8.1 Figure 1**

290 *Figure 1: Linearity was determined for all targets simultaneously by serial dilution of SARS-*  
291 *CoV-2 cell culture stocks and Vaxigrip Tetraivalent Influenza vaccine in 1:1 cobas PCR Media*  
292 *in eSwab medium. X-axis: dilution factor.*

293

### 294 **8.2 Figure 2**

295 *Figure 2: The SC2/InfIA/InfIB-UCT SC2-CT was compared to the SARS-CoV-2 IVD Target-2 CT*  
296 *(used for quantification and best in regards to linear range) to illustrate correlation with a*  
297 *well-established assay. Red diamond indicates false negative for the multiplex assay. ND =*  
298 *Not detected.*

### 299 **8.3 Supplement Figure 1**

300 Supplement Figure 1: A patient sample was used for two 10-fold dilution series in 1:1 cobas PCR  
301 Media and eSwab medium, one containing Vaxigrip tetraivalent Influenza vaccine in order to rule out  
302 relevant interference of high levels of Influenza-RNA for SARS-CoV-2 detection.

### 303 **8.4 Supplement Figure 2**

304 Supplement Figure 2: Amplification curves of the SC2/InfIA/InfIB-UCT using a Atto425 probe for  
305 detection of RdRp/Hel on channel one. In this fashion, both SARS-CoV-2 targets can be analyzed



306 separately. This leads to increased cross-talk of the Yakima-Yellow probe into Channel 2 due to lower  
307 background fluorescence.

308